Ads
related to: uterine serous cancer survival statistics- Learn More Information
Visit The Patient Site If You Have
Been Newly Or Previously Diagnosed.
- Find Support And Savings
Find Rx Savings, Support, & A
Co-pay Assistance Program.
- Learn More Information
Search results
Results From The WOW.Com Content Network
In the older literature survival rates have been given as 35–50% for stage I–II and 0–15% for stage III and IV uterine papillary serous carcinoma, [4] More recently it was reported that forty-two percent of 138 patients were found disease-free at five years.
Unsurprisingly, 5-year survival decreases as the stage increases. There is a 25% survival rate with a stage III serous carcinoma. Staging: Stage I - Tumour growth limited to ovaries. Stage II - Growth involving one or both ovaries with pelvic extension.
High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic cavity and is mainly found in the ovary.HGSCs make up the majority of ovarian cancer cases [1] and have the lowest survival rates. [2]
The median survival of primary peritoneal carcinomas is usually shorter by 2–6 months time when compared with serous ovarian cancer. Studies show median survival varies between 11.3 and 17.8 months. One study reported 19–40 month median survival (95% CI) with a five-year survival of 26.5%. [medical citation needed]
Uterine cancer effects approximately 3.1% of females during their lifetime. [8] Uterine cancer resulted in 45,000 deaths worldwide in 1990, with this number increasing to 58,000 deaths in 2010. [21] North America and Northern Europe have the highest rates of uterine cancer.
As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with serous differentiation. MMMTs are highly malignant; a stage I tumor has an expected five-year survival rate of 50%, while the overall five-year survival rate is less than 20%. [1] Staging of uterine MMMTs is as follows: [3]
Ads
related to: uterine serous cancer survival statistics